Lexeo Therapeutics Inc., a clinical stage genetic medicine company, has announced a research collaboration with Johnson & Johnson to explore the targeted delivery of AAV gene therapy for cardiovascular diseases. The partnership will combine Lexeo’s expertise in cardiac genetic medicine with Johnson & Johnson’s experience in cardiovascular therapeutics and circulatory technologies, including the use of Impella™ heart pumps. The agreement aims to accelerate the development of a preclinical cardiac target by investigating novel, localized routes of gene therapy administration, with the goal of improving the efficacy and safety of treatments for genetically mediated cardiovascular diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621709-en) on January 08, 2026, and is solely responsible for the information contained therein.